MicroRNA-146a in autoimmunity and innate immune responses

Annals of the Rheumatic Diseases

Volumn 72, Issue SUPPL. 2, 2013, Pages

  Chan, Edward K L ^a   Ceribelli, Angela ^a   Satoh, Minoru ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; ENDOTOXIN; MESSENGER RNA; MICRORNA 146A;

3' UNTRANSLATED REGION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; CROSS TOLERANCE; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RNA DEGRADATION; RNA TRANSLATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

AUTOIMMUNITY; ENDOTOXINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; MICRORNAS;

EID: 84876285817     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202203     Document Type: Article

References (64)

1. Keene JD. Minireview: global regulation and dynamics of ribonucleic acid. Endocrinology 2010;151:1391-7.
2. Schott J, Stoecklin G. Networks controlling mRNA decay in the immune system. Wiley Interdisciplinary Reviews RNA 2010;1:432-56.
3. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012;19:586-93.
4. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011;12:99-110.
5. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610.
6. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.
7. Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43:371-8.
8. Garchow BG, Bartulos Encinas O, Leung YT, et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med 2011;3:605-15.
9. Eystathioy T, Chan EKL, Tenenbaum SA, et al. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell 2002;13:1338-51. (Pubitemid 34309627)
10. Yang Z, Jakymiw A, Wood MR, et al. GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci 2004;117:5567-78. (Pubitemid 40012203)
11. Eystathioy T, Jakymiw A, Chan EKL, et al. The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. RNA 2003;9:1171-3. (Pubitemid 37151671)
12. Jakymiw A, Pauley KM, Li S, et al. The role of GW/P-bodies in RNA processing and silencing. J Cell Sci 2007;120:1317-23. (Pubitemid 46780024)
13. Jakymiw A, Lian S, Eystathioy T, et al. Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol 2005;7:1267-74.
14. Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009;457:405-12.
15. Jagannath A, Wood MJ. Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. Mol Biol Cell 2009;20:521-9.
16. Lian S, Fritzler MJ, Katz J, et al. Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. Mol Biol Cell 2007;18:3375-87. (Pubitemid 47378678)
17. Pauley KM, Eystathioy T, Jakymiw A, et al. Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep 2006;7:904-10. (Pubitemid 44523970)
18. Stinton LM, Swain M, Myers RP, et al. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol 2011;163:147-56.
19. Bhanji RA, Eystathioy T, Chan EKL, et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007;125:247-56. (Pubitemid 350116708)
20. Tan EM, Chan EKL, Sullivan KF, et al. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 1988;47:121-41.
21. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151. (Pubitemid 19090837)
22. Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008;58:1284-92. (Pubitemid 351705917)
23. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008;58:1001-9. (Pubitemid 351564001)
24. Pauley KM, Satoh M, Chan AL, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008;10:R101.
25. Tang Y, Luo X, Cui H, et al. miR-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2008;60:1065-75.
26. Chan EKL, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need? Arthritis Rheum 2009;60:912-15.
27. Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010;12:R86.
28. Li J, Wan Y, Guo Q, et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R81.
29. Niimoto T, Nakasa T, Ishikawa M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010;11:209.
30. Abou-Zeid A, Saad M, Soliman E. MicroRNA 146a expression in rheumatoid arthritis: association with tumor necrosis factor-alpha and disease activity. Genet Test Mol Biomark 2011;15:807-12.
31. Pauley KM, Satoh M, Pauley BA, et al. Formation of GW/P bodies as marker for microRNA-mediated regulation of innate immune signaling in THP-1 cells. Immunol Cell Biol 2010;88:205-12.
32. Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006;103:12481-6. (Pubitemid 44267285)
33. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-94. (Pubitemid 32222977)
34. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987;316:379-85. (Pubitemid 17034263)
35. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010;465:885-90.
36. McCall CE, Grosso-Wilmoth LM, LaRue K, et al. Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993;91:853-61. (Pubitemid 23095259)
37. Beeson PB. Tolerance to bacterial pyrogens: I. Factors influencing its development. J Exp Med 1947;86:29-38.
38. Zuckerman SH, Evans GF, Snyder YM, et al. Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J Immunol 1989;143:1223-7. (Pubitemid 19211351)
39. Ulevitch RJ, Wolfson N, Virca GD, et al. Macrophages regulate the host response to bacterial lipopolysaccharides. Prog Clin Biol Res 1989;299:193-202.
40. Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446-58. (Pubitemid 40835033)
41. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-58. (Pubitemid 44298214)
42. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2010;29:447-91.
43. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
44. Nahid MA, Pauley KM, Satoh M, et al. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem 2009;284:34590-9.
45. Wang JF, Yu ML, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010;394:184-8.
46. Biswas SK, Bist P, Dhillon MK, et al. Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance. J Immunol 2007;179:4083-92.
47. de Vos AF, Pater JM, van den Pangaart PS, et al. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 2009;183:533-42.
48. Beutler B. SHIP, TGF-beta, and endotoxin tolerance. Immunity 2004;21:134-5.
49. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353-64. (Pubitemid 46674493)
50. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101:36-47.
51. Dalpke AH, Lehner MD, Hartung T, et al. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 2005;116:203-12. (Pubitemid 41368662)
52. Krishnan J, Selvarajoo K, Tsuchiya M, et al. Toll-like receptor signal transduction. Exp Mol Med 2007;39:421-38. (Pubitemid 47443856)
53. Nahid MA, Satoh M, Chan EKL. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol 2011;186:1723-34.
54. Nakasa T, Shibuya H, Nagata Y, et al. The inhibitory effect of microRNA-146 expression on bone destruction in arthritis. Arthritis Rheum 2011;63:1582-90.
55. Yamasaki K, Nakasa T, Miyaki S, et al. Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis Rheum 2009;60:1035-41.
56. Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol 2011;41:2029-39.
57. Zilahi E, Tarr T, Papp G, et al. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjogren's syndrome. Immunol Lett 2012;141:165-8.
58. Lukiw WJ, Dua P, Pogue AI, et al. Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome. J Toxicol Environ Health A 2011;74:1460-8.
59. Cui JG, Li YY, Zhao Y, et al. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 2010;285:38951-60.
60. Guo M, Mao X, Ji Q, et al. miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome. Immunol Cell Biol 2010;88:555-64.
61. Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010;142:914-29.
62. Lin SL, Chiang A, Chang D, et al. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008;14:417-24. (Pubitemid 351397806)
63. Xu T, Zhu Y, Wei QK, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008;29:2126-31.
64. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011;208:1189-201.